Peptide-Conjugated Quantum Dots Act as the Target Marker for Human Pancreatic Carcinoma Cells

Li, Shuangling; Yang, Jing; Lei, Xiaofei; Zhang, Jianna; Yang, Hai; Li, Kun; Xu, Changqing

doi:10.1159/000443062

Cited by 11 publications

(2 citation statements)

References 26 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, CA19-9 levels are also elevated in some benign diseases, such as liver disease and pancreatitis [26]. There are also some potential pancreatic cancer markers reported in recent years [27][28][29][30].…”

Section: Discussionmentioning

confidence: 99%

Circulating Tumor DNA as a Sensitive Marker in Patients Undergoing Irreversible Electroporation for Pancreatic Cancer

Lin

Alnaggar

Liang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at an advanced stage, resulting in extremely poor 5-year survival. Late diagnosis of PDAC is mainly due to lack of a reliable method of early detection. Carbohydrate antigen (CA) 19-9 is often used as a tumor biomarker in PDAC; however, the test lacks sensitivity and specificity. Therefore, new sensitive and minimally invasive diagnostic tools are required to detect pancreatic cancer. Methods: Here, we investigated circulating tumor DNA (ctDNA) which contained KRAS-mutated as a potential diagnostic tool for PDAC patients who underwent irreversible electroporation (IRE). We used droplet digital polymerase chain reaction (ddPCR) to detect the expression of KRAS-mutated genes in plasma samples of 65 PDAC patients who underwent IRE. Results: In these 65 cases, ctDNA was detected in 20 (29.2%) samples. The median overall survival (OS) was 11.4 months with ctDNA+ patients and 14.3 months for ctDNA- patients. ctDNA+ patients had a obviously poorer prognosis associated to overall survival (P < 0.001). Conclusion: Our results suggested that the existence of ctDNA was a predictor of survival for PDAC patients. Therefore, ctDNA may be a new sensitive biomarker for monitoring treatment outcome in PDAC.

show abstract

Section: Discussionmentioning

confidence: 99%

Circulating Tumor DNA as a Sensitive Marker in Patients Undergoing Irreversible Electroporation for Pancreatic Cancer

Lin

Alnaggar

Liang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…Quantum dots (QDs) are nanomaterials with unique fluorescence properties that have promising applications in tumor imaging and early detection [126,127]. The QDs-RGD probe coupled with RGD peptide showed an obvious tumor imaging effect in SW1990 pancreatic tumor model [128]. When QDs-RGD NPs were combined with gemcitabine, the tumor inhibition rate of the combined treatment group (QDs-RGD NPs+ laser irradiation + gemcitabine) was much higher than that of the gemcitabine group alone, suggesting that QDs-RGD NPs has a synergistic effect on inhibiting the proliferation of SW1990 pancreatic tumors.…”

Section: Inorganic Nanomaterialsmentioning

confidence: 99%

The Role of Integrins for Mediating Nanodrugs to Improve Performance in Tumor Diagnosis and Treatment

Jiang

et al. 2023

Nanomaterials

View full text Add to dashboard Cite

Integrins are heterodimeric transmembrane proteins that mediate adhesive connections between cells and their surroundings, including surrounding cells and the extracellular matrix (ECM). They modulate tissue mechanics and regulate intracellular signaling, including cell generation, survival, proliferation, and differentiation, and the up-regulation of integrins in tumor cells has been confirmed to be associated with tumor development, invasion, angiogenesis, metastasis, and therapeutic resistance. Thus, integrins are expected to be an effective target to improve the efficacy of tumor therapy. A variety of integrin-targeting nanodrugs have been developed to improve the distribution and penetration of drugs in tumors, thereby, improving the efficiency of clinical tumor diagnosis and treatment. Herein, we focus on these innovative drug delivery systems and reveal the improved efficacy of integrin-targeting methods in tumor therapy, hoping to provide prospective guidance for the diagnosis and treatment of integrin-targeting tumors.

show abstract

Exploring the Modern Bioactive Peptides (BAPs) Universe: Doors to the Future

Patil

2024

Peptide Science

View full text Add to dashboard Cite

Because of their wide variety of biological effects, bioactive peptides (BAPs) have recently attracted a lot of attention. BAPs have been observed to be safe, thanks to their widely acknowledged safety status by the United States Food and Drug Administration (USFDA). This has led to their widespread use in various industries, such as food and nutrition, pharmaceuticals, and therapeutics. A considerable amount of research has been devoted to developing cutting‐edge nanomaterials derived from BAPs, which have been utilized in a wide range of industries. In the realm of scientific research, the remarkable ability of BAPs to self‐assemble has been harnessed to develop a wide range of nanoassemblies. These nanoassemblies hold immense potential for the advancement of biomaterials in the future. Research interest continues to focus on the study of the detection of BAPs using artificial intelligence (AI). Over the past few years, there has been a surge of interest in utilizing bio‐inspired strategies to explore new possibilities in the development of advanced energy devices and storage solutions. However, these strategies require scientific attention. This extensive review offers a broad perspective on the applications of BAPs in nanotechnology as well as pharmaceuticals and therapeutics. Moreover, in silico analysis of BAPs, coupled with ‐omics techniques, has been discussed. In the bargain, the next‐generation approaches in BAP research comprising BAP‐based energy devices, as well as BAPs in AI, have been catalogued. There is a considerable emphasis on developing more eco‐friendly energy‐storage technologies that draw inspiration from nature and use BAPs.

show abstract

Peptide-Conjugated Quantum Dots Act as the Target Marker for Human Pancreatic Carcinoma Cells

Cited by 11 publications

References 26 publications

Circulating Tumor DNA as a Sensitive Marker in Patients Undergoing Irreversible Electroporation for Pancreatic Cancer

Circulating Tumor DNA as a Sensitive Marker in Patients Undergoing Irreversible Electroporation for Pancreatic Cancer

The Role of Integrins for Mediating Nanodrugs to Improve Performance in Tumor Diagnosis and Treatment

Exploring the Modern Bioactive Peptides (BAPs) Universe: Doors to the Future

Contact Info

Product

Resources

About